TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06084936: A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 182 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06084936 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06084936 Rescue Dossier →